Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > About JDRF & Our Impact > Our research > Research projects > Improving islet transplants to treat type 1 diabetes
For the first time, we are co-funding a research project with the Medical Research Council (MRC). Together, we are supporting Daniel Doherty to complete his PhD, which will focus on improving the outcome of islet transplants for people with type 1.
The islets in the pancreas are home to the insulin-producing beta cells, which are destroyed in type 1. Islet transplants take islets from donated pancreases and put them into the livers of people with type 1. They are only available to people who are really struggling to manage their type 1 due to the risks associated with the immunosuppressant drugs required. Even with the low numbers of people who need islet transplants, there are not enough organ donors for everyone.
Currently, several organ donors are needed to gather enough islets for just one transplant. This is partly because many islets don’t survive the transplant. Even the cells that do survive only last a few years, when patients will need another islet transplant. Dan’s research aims to combat this by creating a more supportive environment for islet cells in the liver to boost their survival. This will help people who receive islet transplants produce insulin more effectively and require transplants less frequently. It will also enable more people to benefit from islet transplants.
Using sophisticated techniques, Dan is learning more about how transplanted islets and their neighbouring cells in the liver influence each other. Islets are placed into the liver because it is much easier to get to than the pancreas, which is tucked deep inside the body. Dan is investigating how the liver responds to islets being placed there and why many islets don’t survive.
Researcher Daniel Doherty in the lab
Through his careful research, Dan has identified patterns in the extracellular matrix around the islets and signs of liver injury. The extracellular matrix is a complex network of molecules outside of cells, which link together to form the structure of organs. Fibroblasts are a type of cell that produces key components of this extracellular matrix. Dan is growing pancreatic islets along with fibroblasts in his lab to learn more about how they interact. He thinks this could provide important information about how he can make islets last longer and work better.
Dan will look carefully at pancreas samples from people without type 1 to understand which cell types are present and how they support the islets. He will compare this with the cells that he has found around the islets once they are in the liver. This will tell Dan which cells could be transplanted with the islets to help support them in the liver.
Aside from improving islet transplants, Dan’s findings are transferable to stem cell-derived therapies, where scientists grow insulin-producing cells in their labs from stem cells, which can develop into lots of other cell types. Dan’s research will provide useful insight to boost these cells’ function and survival. Most other research in this area aims to generate as many high-quality insulin-producing cells as possible. Dan’s focus on the supportive structures is crucial for creating healthier islets and supporting them once they have been transplanted into people with type 1.
Dan’s work will help people with type 1 who need islet transplants as well as supporting cure research of stem cell therapies. If more islets can survive both types of treatment, the people with type 1 who receive them will be able to produce insulin more effectively. In the short-term, this research will help limit the number of repeat islet transplants required, making them available for more people with type 1. In the long-term, we hope Dan’s research will contribute to improving stem cell therapies as a cure for type 1.
Alongside this project, Dan is interviewing people with type 1 who have received or are waiting to receive a pancreas transplant to help more people benefit from the treatment. He is developing a guide for doctors to maximise the number of transplants from available donors. If you would like to help Dan improve pancreas transplant surgery in the UK, email him on email@example.com
Learn more about Dan’s research in this video he created: Minute Lecture: Can Transplants Fix Diabetes?
We are funding Dr Rocio Sancho to develop a supportive gel to grow beta cells in. Like Dan, Rocio aims to create an environment that mimics the human pancreas to improve the quality of her beta cells. While Dan is focusing on islets from organ donors, Rocio is growing her beta cells from stem cells in an artificial growth gel.
Dr Leslie Johnson will explore whether a collaborative care model that is effective for type 2 diabetes can be adapted for people with type 1.
Dr Chloe Rackham is investigating how supportive cells called mesenchymal stem cells may help protect people from developing type 1.
Dr Ify Mordi is an expert in heart disease and diabetes at the University of Dundee. We are funding Ify to run the first clinical trial of the drug sotagliflozin in people living with type 1 diabetes and heart failure.
We are funding Professor Timothy Tree and his team at King’s College London to support clinical trials of ustekinumab in young people recently diagnosed with type 1 diabetes. The team is analysing blood samples from people taking part in the clinical trials USTEKID and UST1D2.